AZD0530 to Treat Recurrent Stage IIIB/IV NSCLC Previously Treated With Combination Chemotherapy
Status:
Completed
Trial end date:
2013-06-01
Target enrollment:
Participant gender:
Summary
This phase II trial is studying how well saracatinib works in treating patients with
recurrent, stage IIIB or stage IV non-small cell lung cancer previously treated with
combination chemotherapy that included cisplatin or carboplatin. Saracatinib may stop the
growth of tumor cells by blocking some of the enzymes needed for cell growth.